AXGNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Axogen, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$35.24+0.62 (+1.79%)

Close on Oct 19, 2026

Market cap: $1.88B
P/E (TTM): –
Dividend yield: –

Dividends

Axogen has not reported a dividend

No dividend per share appears in Axogen's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Axogen's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AXGN.

Revenue growth23.6% · median 1.0%

Gross margin74.6% · median 80.2%

Operating margin-5.1% · median 2.5%

Net margin-13.4% · median 1.8%

Company	Revenue	Growth
MDXG	$355.17M	-2.4%
AXGN	$251.17M	+23.6%
BLFS	$102.82M	+25.4%
RCEL	$75.63M	+1.0%
INMD	–	–
FOCL	–	–

Company

Next earnings (est.): Oct 28, 2026, before open
Exchange: Nasdaq
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: December 31
Employees: 622
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 805928

Advertisement
300 × 250